The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.
A billionaire entrepreneur is taking his highly valued firm NantHealth public.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
The gene editing firm will concurrently offer 5 million shares to the public and $55 million worth of shares at the same price in a private placement.
BGI is seeking an IPO on a Shenzhen-based stock exchange, but the timing of when this might occur is unclear, FinanceAsia reports.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.
The Cambridge, Massachusetts-based gene editing firm will offer 5.9 million shares of common stock, for a total of $94.4 million.
The Cambridge, Massachusetts-based CRISPR therapy firm expects to price shares between $16 and $18.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.